Helicobacter pylori is a major human pathogen for which increasing antibiotic resistance
constitutes a serious threat to human health. Molecular mechanisms underlying this …

Worldwide, bacterial resistance to chemical antibiotics has reached such a high level that
endangers public health. Presently, the adoption of alternative strategies that promote the …

Infectious diseases claim millions of lives every year, but with the advent of drug resistance,
therapeutic options to treat infections are inadequate. There is now an urgent need to …

This review examines the vast catalytic and therapeutic potential offered by type I (ie oxygen-
insensitive) nitroreductase enzymes in partnership with nitroaromatic prodrugs, with …

Helicobacter pylori infects approximately 50% of the world's population and is considered
the major etiological agent of severe gastric diseases, such as peptic ulcers and gastric …

Giardia duodenalis is a microaerophilic parasite of the human gastrointestinal tract and a
major contributor to diarrheal and post-infectious chronic gastrointestinal disease world …

Helicobacter pylori is a gram-negative bacterium that colonizes the stomach of
approximately half of the worldwide population, with higher prevalence in densely populated …

TNP-2198, a stable conjugate of a rifamycin pharmacophore and a nitroimidazole
pharmacophore, has been designed, synthesized, and evaluated as a novel dual-targeted …

Nitroaromatic antibiotics show activity against anaerobic bacteria and parasites, finding use
in the treatment of Heliobacter pylori infections, tuberculosis, trichomoniasis, human African …

Metronidazole (MNZ) is administered as first-line antibiotic for Helicobacter pylori
eradication therapy; however, increasing resistance to MNZ impaired the efficacy. Increasing …